201 related articles for article (PubMed ID: 8027985)
1. Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2'-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide).
Rewcastle GW; Palmer BD; Dobrusin EM; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1994 Jun; 37(13):2033-42. PubMed ID: 8027985
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases.
Palmer BD; Rewcastle GW; Thompson AM; Boyd M; Showalter HD; Sercel AD; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1995 Jan; 38(1):58-67. PubMed ID: 7837241
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors. 2. Synthesis of 2,2'-dithiobis(1H-indole-3-alkanamides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases.
Thompson AM; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1994 Mar; 37(5):598-609. PubMed ID: 7510340
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids).
Thompson AM; Rewcastle GW; Tercel M; Dobrusin EM; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1993 Aug; 36(17):2459-69. PubMed ID: 8355247
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and pp60c-Src tyrosine kinase inhibitory activities of novel indole-3-imine and amine derivatives substituted at N1 and C5.
Kiliç Z; Isgör YG; Olgen S
Arch Pharm (Weinheim); 2009 Jun; 342(6):333-43. PubMed ID: 19475593
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C
J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163
[TBL] [Abstract][Full Text] [Related]
9. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
10. Comparison of some 3-(substituted-benzylidene)-1,3-dihydroindolin derivatives as ligands of tyrosine kinase based on binding mode studies and biological assay.
Olgen S
Arch Pharm Res; 2006 Nov; 29(11):1006-17. PubMed ID: 17146970
[TBL] [Abstract][Full Text] [Related]
11. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anti-tyrosine kinase activity of 3-(substituted-benzylidene)-1, 3-dihydro-indolin derivatives: investigation of their role against p60c-Src receptor tyrosine kinase with the application of receptor docking studies.
Olgen S; Akaho E; Nebioglu D
Farmaco; 2005; 60(6-7):497-506. PubMed ID: 15927182
[TBL] [Abstract][Full Text] [Related]
13. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
[TBL] [Abstract][Full Text] [Related]
14. Nonphosphorylatable substrate analogs selectively block autophosphorylation and activation of the insulin receptor, epidermal growth factor receptor, and pp60v-src kinases.
Shoelson SE; White MF; Kahn CR
J Biol Chem; 1989 May; 264(14):7831-6. PubMed ID: 2498306
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr, and p60v-src.
Cushman M; Zhu H; Geahlen RL; Kraker AJ
J Med Chem; 1994 Sep; 37(20):3353-62. PubMed ID: 7932563
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60(c-src).
Thompson AM; Rewcastle GW; Boushelle SL; Hartl BG; Kraker AJ; Lu GH; Batley BL; Panek RL; Showalter HD; Denny WA
J Med Chem; 2000 Aug; 43(16):3134-47. PubMed ID: 10956222
[TBL] [Abstract][Full Text] [Related]
17. Marine sponge polyketide inhibitors of protein tyrosine kinase.
Lee RH; Slate DL; Moretti R; Alvi KA; Crews P
Biochem Biophys Res Commun; 1992 Apr; 184(2):765-72. PubMed ID: 1315532
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors.
Fry DW; Nelson JM
Anticancer Drug Des; 1995 Dec; 10(8):607-22. PubMed ID: 8595121
[TBL] [Abstract][Full Text] [Related]
19. Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase.
Mahboobi S; Teller S; Pongratz H; Hufsky H; Sellmer A; Botzki A; Uecker A; Beckers T; Baasner S; Schächtele C; Uberall F; Kassack MU; Dove S; Böhmer FD
J Med Chem; 2002 Feb; 45(5):1002-18. PubMed ID: 11855980
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
